Table 3.

Main pharmacokinetic parameters obtained during the monitoring period

	CsA group
	C0 MPAtot	C0 fMPA	fu	C2 MPAtot	C2 fMPA	fu	AUC0–12 h
Month	(µg ml−1)	(µg ml−1)	(%)	(µg ml−1)	(µg ml−1)	(%)	(µg h ml−1)
0	2.2 ± 1.6	0.033 ± 0.017	2.0 ± 1.9	8.0 ± 5.5	0.098 ± 0.032	1.4 ± 0.9	48.2 ± 21.2
2	1.6 ± 0.5	0.032 ± 0.020	2.0 ± 1.3	7.7 ± 4.7	0.104 ± 0.030	1.8 ± 1.0	37.9 ± 13.1
4	2.8 ± 2.7	0.039 ± 0.018	2.1 ± 1.4	9.3 ± 5.5	0.089 ± 0.024	1.4 ± 1.2	50.3 ± 21.3
6	1.6 ± 0.7	0.030 ± 0.010	2.0 ± 0.8	6.7 ± 4.4	0.106 ± 0.042	2.0 ± 0.9	32.1 ± 14.5
8	2.8 ± 3.0	0.029 ± 0.015	1.7 ± 1.1	7.5 ± 2.9	0.116 ± 0.079	1.7 ± 1.1	44.9 ± 16.1
10	2.5 ± 2.7	0.027 ± 0.018	1.5 ± 0.7	5.8 ± 3.0	0.097 ± 0.050	1.7 ± 0.4	39.7 ± 14.8
12	2.8 ± 1.3	0.033 ± 0.014	1.5 ± 0.5	9.1 ± 6.3	0.134 ± 0.079	1.7 ± 0.7	50.9 ± 19.7
15	2.8 ± 2.1	0.022 ± 0.011	1.2 ± 0.8	6.0 ± 4.1	0.100 ± 0.059	1.8 ± 1.1	38.2 ± 12.4
Total	2.3 ± 1.9	0.035 ± 0.017	2.0 ± 1.2	7.7 ± 4.8	0.105 ± 0.048*	1.7 ± 0.9	42.0 ± 17.5
	Tac group
	C0 MPAtot	C0 fMPA	fu	C2 MPAtot	C2 fMPA	fu	AUC0–12 h
Month	(µg ml−1)	(µg ml−1)	(%)	(µg ml−1)	(µg ml−1)	(%)	(µg h ml−1)
0	3.6 ± 3.1	0.035 ± 0.026	1.3 ± 1.0	7.9 ± 3.6	0.109 ± 0.081	1.4 ± 1.1	56.9 ± 25.9
2	2.4 ± 2.2	0.030 ± 0.020	1.5 ± 1.0	4.7 ± 2.8	0.060 ± 0.049	1.2 ± 0.6	41.8 ± 19.5
4	2.0 ± 1.3	0.032 ± 0.039	1.8 ± 2.8	4.7 ± 2.5	0.054 ± 0.025	1.2 ± 0.3	39.1 ± 12.2
6	2.4 ± 1.4	0.033 ± 0.018	1.3 ± 0.6	5.2 ± 2.5	0.069 ± 0.031	1.4 ± 0.4	41.4 ± 14.0
8	2.3 ± 1.6	0.031 ± 0.019	1.5 ± 0.9	3.8 ± 2.1	0.043 ± 0.023	1.2 ± 0.4	38.0 ± 12.5
10	2.4 ± 1.5	0.032 ± 0.021	2.0 ± 2.0	5.1 ± 2.5	0.050 ± 0.019	1.1 ± 0.4	42.9 ± 12.9
12	2.2 ± 1.2	0.040 ± 0.035	1.7 ± 0.8	4.9 ± 2.3	0.063 ± 0.056	1.2 ± 0.5	40.5 ± 10.8
15	2.7 ± 2.2	0.041 ± 0.048	2.4 ± 4.1	4.8 ± 2.9	0.049 ± 0.027	1.1 ± 0.4	37.3 ± 8.2
Total	2.6 ± 2.1	0.033 ± 0.028	1.9 ± 2.8	5.5 ± 3.0	0.068 ± 0.054	1.3 ± 0.6	44.6 ± 19.2
	Sir group
	C0 MPAtot	C0 fMPA	fu	C2 MPAtot	C2 fMPA	fu	AUC0–12 h
Month	(µg ml−1)	(µg ml−1)	(%)	(µg ml−1)	(µg ml−1)	(%)	(µg h ml−1)
0	2.9 ± 1.7	0.039 ± 0.021	1.5 ± 0.6	6.3 ± 3.4	0.069 ± 0.048	1.3 ± 0.9	NA
2	4.3 ± 1.9	0.032 ± 0.021	0.8 ± 0.3	6.3 ± 3.6	0.057 ± 0.036	0.9 ± 0.3	NA
4	3.0 ± 1.9	0.035 ± 0.017	1.3 ± 0.4	5.4 ± 3.8	0.052 ± 0.037	1.1 ± 0.4	NA
6	1.3 ± 1.9	0.030 ± 0.016	2.4 ± 0.5	2.1 ± 2.2	0.054 ± 0.052	2.7 ± 0.4	NA
8	3.7 ± 2.6	0.042 ± 0.020	1.4 ± 0.8	6.3 ± 4.2	0.103 ± 0.068	1.3 ± 0.9	NA
10	2.5 ± 1.5	0.040 ± 0.022	2.0 ± 1.5	5.4 ± 4.5	0.062 ± 0.023	2.0 ± 1.7	NA
12	2.3 ± 1.6	0.030 ± 0.015	1.5 ± 0.5	6.7 ± 6.3	0.065 ± 0.046	1.9 ± 1.2	NA
15	2.1 ± 0.2	0.028 ± 0.008	1.3 ± 0.4	4.4 ± 2.4	0.060 ± 0.030	0.9 ± 0.4	NA
Total	3.0 ± 1.9	0.036 ± 0.019	1.4 ± 0.8	6.2 ± 4.3	0.072 ± 0.048	1.4 ± 1.0	NA

Data are expressed as means ± SD. NA, not applicable;

^*P= 0.001 vs. Tac and P= 0.021 vs. Sir. CsA, ciclosporin; Tac, tacrolimus; Sir, sirolimus; MPA, mycophenolic acid.